Core Insights - Baiyang Pharmaceutical (301015.SZ) has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center focused on brain tumors, utilizing the ZAP-X robotic system to provide innovative treatment solutions for millions of patients [2][4]. Group 1: Strategic Partnership - The collaboration aims to create a high-level radiotherapy platform that specializes in the treatment of brain tumors, addressing the increasing incidence of such conditions globally [2][4]. - The ZAP-X system is recognized as a revolutionary technology in cranial radiotherapy, enhancing precision and safety in treatment by targeting tumors from multiple angles while protecting surrounding healthy brain tissue [4][5]. Group 2: Market Context - The global incidence of brain tumors is rising, with over 1.5 million new cases of brain metastases reported annually in China alone, highlighting the urgent need for advanced treatment options [4][6]. - Baiyang Pharmaceutical is transitioning into a technology-driven enterprise, establishing a comprehensive ecosystem in the radiotherapy sector that includes brain, body, and cardiac treatment solutions [6]. Group 3: Future Developments - Baiyang plans to accelerate the clinical application of ZAP-X in China and aims to establish a global manufacturing and supply center for the device by the end of 2025 [6]. - The company is also developing innovative technologies, such as the first 4π intelligent robotic radiotherapy system and exploring non-invasive treatments for arrhythmias, further solidifying its position in the global precision radiotherapy market [6].
百洋医药首家放疗中心落地北京大学国际医院，引领脑肿瘤精准放疗新格局